Evidence map›Paper›PMID 24713807›Full record

ArticlePloS one2014

Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line.

James M Wagner, J David Pajerowski, Christopher L Daniels, Patrick M McHugh, Jessica A Flynn, John W Balliet, Danilo R Casimiro, Shyamsundar Subramanian

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Chikungunya vaccines in development.Human vaccines & immunotherapeutics · 2016
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

James M WagnerVaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
J David PajerowskiVaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
Christopher L DanielsVaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
Patrick M McHughVaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
Jessica A FlynnVaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
John W BallietVaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
Danilo R CasimiroVaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.
Shyamsundar SubramanianVaccine Research and Development, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chikungunya virus-like particles (VLPs) have potential to be used as a prophylactic vaccine based on testing in multiple animal models and are currently being evaluated for human use in a Phase I clinical trial. The current method for producing these enveloped alphavirus VLPs by transient gene expression in mammalian cells presents challenges for scalable and robust industrial manufacturing, so the insect cell baculovirus expression vector system was evaluated as an alternative expression technology. Subsequent to recombinant baculovirus infection of Sf21 cells in standard culture media (pH 6.2-6.4), properly processed Chikungunya structural proteins were detected and assembled capsids were observed. However, an increase in culture pH to 6.6-6.8 was necessary to produce detectable concentrations of assembled VLPs. Since this elevated production pH exceeds the optimum for growth medium stability and Sf21 culture, medium modifications were made and a novel insect cell variant (SfBasic) was derived by exposure of Sf21 to elevated culture pH for a prolonged period of time. The high-pH adapted SfBasic insect cell line described herein is capable of maintaining normal cell growth into the typical mammalian cell culture pH range of 7.0-7.2 and produces 11-fold higher Chikungunya VLP yields relative to the parental Sf21 cell line. After scale-up into stirred tank bioreactors, SfBasic derived VLPs were chromatographically purified and shown to be similar in size and structure to a VLP standard derived from transient gene expression in HEK293 cells. Total serum anti-Chikungunya IgG and neutralizing titers from guinea pigs vaccinated with SfBasic derived VLPs or HEK293 derived VLPs were not significantly different with respect to production method, suggesting that this adapted insect cell line and production process could be useful for manufacturing Chikungunya VLPs for use as a vaccine. The adaptation of Sf21 to produce high levels of recombinant protein and VLPs in an elevated pH range may also have applications for other pH-sensitive protein or VLP targets.

Indexed as

Virus ReplicationAnimalsCapsidCell Culture TechniquesCell LineChikungunya virusGene ExpressionGuinea PigsHumansHydrogen-Ion ConcentrationRecombinant ProteinsSpodopteraViral Structural ProteinsVirionRecombinant ProteinsViral Structural Proteins

Identifiers

PMID24713807
PMCPMC3979839
OpenAlexW2039207244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.